Reimbursement: economics of orphan drugs and the impact of rarity on the estimation of cost effectiveness ration

Increasing pressures on health care budgets have led to a growing interest in the use of economic evaluation in reimbursement decisions for drugs and other health technologies. This has a great impact in the access of orphan drugs by rare disease patients. In this scenario, insurance companies are starting to assess the value for money by comparing the incremental costs …